Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) Director Marc Duey purchased 30,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were bought at an average cost of $4.39 per share, with a total value of $131,700.00. Following the acquisition, the director now directly owns 240,113 shares of the company’s stock, valued at $1,054,096.07. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Marc Duey also recently made the following trade(s):
- On Monday, October 14th, Marc Duey purchased 190 shares of Aprea Therapeutics stock. The shares were bought at an average cost of $2.58 per share, with a total value of $490.20.
Aprea Therapeutics Stock Up 27.1 %
Shares of Aprea Therapeutics stock opened at $4.45 on Friday. The stock’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $4.19. Aprea Therapeutics, Inc. has a 52 week low of $2.15 and a 52 week high of $8.85. The company has a market capitalization of $24.16 million, a price-to-earnings ratio of -1.34 and a beta of 1.03.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on APRE. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a research report on Monday, August 12th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.
Check Out Our Latest Analysis on APRE
Institutional Investors Weigh In On Aprea Therapeutics
An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Read More
- Five stocks we like better than Aprea Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
- Insider Trades May Not Tell You What You Think
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
- Most active stocks: Dollar volume vs share volume
- Insider Selling is not a Signal to Start Selling Gartner Stock
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.